🤑 Let’s talk about Biotech.🤑

Particularly, an overlooked exit strategy — IPO at HKEX.

Table of Contents

• 🤑 Let’s talk about Biotech.🤑

  • I. Preview

  • II. Technical Things

    • A. Clinical Trials

    • B. IND Submissions

    • C. IPO at HKEX 🤑

    • Chapter 18A Listing Rules of HKEX

I. Preview

Pouring myself a coffee from the French-pressed jar, I wondered what I should do this sunny morning. My conversation with Igor, the leader of the iGEM Munich team, on the U-Bahn to Senderlinger Tor the previous day reminded me of a bittersweet business I swallowed long ago—clinical trials, startup, IPO...

This sounds like the beginning of a long essay, but sadly it is not. Instead, this is just an overview of how a therapy product goes from clinical trial to a significant financial return.

Before we dive into any details, I hope everyone reading this guide will keep their flame of the pursuit of science and truth unaltered. Meanwhile, it is confusingly ridiculous how easy it can be to make a considerable fortune without actually knowing the science behind a cell therapy product by building a biotech startup and exiting through initial public offerings (IPO) in the Hong Kong Exchanges and Clearing Limited (HKEX).

I will talk about three things here.

• A. Clinical Trials

• B. Investigational New Drug (IND) submissions

• C. IPO at HKEX

II. Technical Things

A. Clinical Trials

CAR-T cell therapy and Immunotherapy

Immunotherapy has immense potential in curing diseases of the highest urgency and importance, such as cancers, leukemia, solid tumors, and neurodegenerative disorders.

Over the past five years, over 1,000 clinical trials of CAR-T cell therapy products have been registered on www.clinicaltrials.gov. to bring the latest type of therapy, which aims to have improved efficacy and safety, to the patient's bedside.

Subscribe to Infinity You to read the rest.